Dividend reinvestment adds GSK (NYSE: GSK) ADSs for top executive

Rhea-AI Filing Summary

GSK plc reports that Chief People Officer Diana Conrad acquired 65.267 American Depositary Shares at $58.3499 per ADS on 13 April 2026. The ADSs were acquired through reinvestment of dividends paid on 9 April 2026 on shares held within a GSK pension plan.

Key Figures

ADS volume acquired: 65.267 ADSs ADS purchase price: $58.3499 per ADS Transaction date: 13 April 2026

3 metrics

ADS volume acquired 65.267 ADSs Acquisition for Diana Conrad via dividend reinvestment

ADS purchase price $58.3499 per ADS Price for the April 13, 2026 acquisition

Transaction date 13 April 2026 Date ADSs were acquired on NYSE (XNYS)

Key Terms

American Depositary Shares, dividends paid, pension plan, PDMR, +1 more

5 terms

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares ('ADS')"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

dividends paid financial

"reinvestment of dividends paid to shareholders on 9 April 2026"

pension plan financial

"on shares held within GSK pension plan"

A pension plan is a long-term program set up to pay retirees a regular income after they stop working, funded by employers, employees, or both. For investors, pension plans matter because they represent large pools of invested money that can move markets, create long-term demand for assets, and pose financial risks if promised payments exceed available funds — think of it as a community savings pot that must be managed carefully to meet future bills.

PDMR regulatory

"Details of PDMR/person closely associated with them ('PCA')"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

LEI regulatory

"LEI | 5493000HZTVUYLO1D793"

A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Diana Conrad
b)	Position/status	Chief People Officer
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ​ ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS following the reinvestment of dividends paid to shareholders on 9 April 2026, on shares held within GSK pension plan.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$58.3499	65.267
		d)	Aggregated information Aggregated volume Price	N/A (single transaction)
e)	Date of the transaction	2026-04-13
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: April 20, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What insider share transaction did GSK (GSK) report in April 2026?

GSK reported that Chief People Officer Diana Conrad acquired 65.267 American Depositary Shares. The shares were bought at $58.3499 each on 13 April 2026 through automatic dividend reinvestment within a GSK pension plan following dividends paid on 9 April 2026.

Who at GSK (GSK) acquired shares according to the April 2026 filing?

The filing shows Chief People Officer Diana Conrad acquired additional GSK American Depositary Shares. She received 65.267 ADSs via dividend reinvestment within a GSK pension plan, reflecting an automatic purchase mechanism rather than an open-market discretionary share purchase.

How many GSK (GSK) ADSs were acquired and at what price?

Diana Conrad acquired 65.267 GSK American Depositary Shares at a price of $58.3499 per ADS. This single transaction resulted from reinvestment of cash dividends paid on 9 April 2026 into additional ADSs held in a company pension arrangement.

What is the nature of the GSK (GSK) insider transaction disclosed?

The transaction is an acquisition of ADSs following dividend reinvestment. Dividends paid on 9 April 2026 on shares in a GSK pension plan were automatically reinvested on 13 April 2026 to purchase 65.267 American Depositary Shares for Chief People Officer Diana Conrad.

On which market were the GSK (GSK) ADSs acquired in this transaction?

The acquired GSK American Depositary Shares were transacted on the New York Stock Exchange. The filing specifies the trading venue as XNYS, confirming the ADS purchase occurred in the U.S. market on 13 April 2026 through the dividend reinvestment process.